Table 2 Response to artemether–lumefantrine treatment
From: Absence of in vivo selection for K13 mutations after artemether–lumefantrine treatment in Uganda
Characteristic | Age | Total (n = 61) | |
|---|---|---|---|
<5 years (n = 49) | ≥5 years (n = 12) | ||
Fever (≥37.5 °C) persistence [n (%)] | |||
Day 1 | 11 (22.4) | 1 (8.3) | 12 (19.7) |
Day 2 | 3 (6.1) | 0 | 3 (4.9) |
Day 3 | 0 | 0 | 0 |
Parasite persistence | |||
Microscopy [n (%)] | |||
Day 1 | 40 (81.6) | 11 (91.7) | 51 (83.6) |
Day 2 | 13 (26.5) | 5 (4.2) | 18 (29.5) |
Day 3 | 1 (2.0) | 0 | 1 (1.6) |
PCR [n (%)] | |||
Day 1 | 45 (91.8) | 11 (91.7) | 56 (91.8) |
Day 2 | 27 (55.1) | 6 (50) | 33 (54.1) |
Day 3 | 11 (22.4) | 3 (25) | 14 (22.9) |
Gametocyte persistence [n (%)] | |||
Day 1 | 4 (8.2) | 1 (8.3) | 5 (8.2) |
Day 2 | 3 (6.1) | 1 (8.3) | 4 (6.6) |
Day 3 | 3 (6.1) | 1 (8.3) | 4 (6.6) |
28-day WHO treatment outcome [n (%)] | |||
Early treatment failure | 0 | 0 | 0 |
Late clinical failure | 2 (4.1) | 1 (8.3) | 3 (4.9) |
Late parasitological failure | 0 | 0 | 0 |
Adequate clinical and parasitological response | 47 (96.0) | 11 (91.7) | 58 (95.1) |
Cure rate [n (%)] | |||
PCR unadjusted | 47 (96.0) | 11 (91.7) | 58 (95.2) |
PCR adjusted | 47 (96.0) | 11 (91.7) | 58 (95.2) |